Lv5
868 积分 2025-10-16 加入
P-175 Improving Anti-BCMA CAR-T functionality with novel immunomodulatory agent Iberdomide (CC220) in Multiple Myeloma
15天前
已关闭
Iberdomide plus low-dose cyclophosphamide and dexamethasone in patients with relapsed and refractory multiple myeloma (the ICON study): a multicentre, single-arm, phase 2 trial
15天前
已完结
EXCALIBER-RRMM: a phase III trial of iberdomide, daratumumab, and dexamethasone in relapsed/refractory multiple myeloma
17天前
已完结
OA-49 Mezigdomide (MEZI) plus dexamethasone (DEX) and bortezomib (BORT) or carfilzomib (CFZ) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): results from the CC-92480-MM-002 trial
1个月前
已完结
Cancer therapies based on targeted protein degradation — lessons learned with lenalidomide
1个月前
已关闭
Large-Scale Mass Cytometry Reveals Significant Activation of Innate and Adaptive Immunity in Bone Marrow Tumor Microenvironment of Iberdomide-Treated Myeloma Patients
1个月前
已关闭
Multiple Myeloma, Version 5.2026, NCCN Clinical Practice Guidelines In Oncology
2个月前
已完结
CSNK1E Sustains Stem-like Drug Persistence in Diffuse Large B-cell Lymphoma
2个月前
已关闭
CSNK1E Sustains Stem-like Drug Persistence in Diffuse Large B-cell Lymphoma
2个月前
已关闭
Iberdomide, bortezomib, and dexamethasone (IberVd) in transplant-ineligible (TNE) newly diagnosed multiple myeloma (NDMM): Updated results from the CC-220-MM-001 trial
2个月前
已关闭
皖公网安备34019202002308
